Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Biosimilar Monoclonal Antibodies market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Biosimilar Monoclonal Antibodies market. Detailed analysis of key players, along with key growth strategies adopted by Biosimilar Monoclonal Antibodies industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Dr Reddy’s
Hisun Pharma
Torrent Pharmaceuticals
Celgen Biopharma
Pfizer (Hospira)
Novartis (Sandoz)
Cadila Healthcare
3SBIO
Celltrion
By Type:
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
By End-User:
Oncology
Autoimmune Disease
Other
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Biosimilar Monoclonal Antibodies Market
-
1.3 Market Segment by Type
-
1.3.1 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Infliximab from 2016 to 2027
-
1.3.2 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Rituximab from 2016 to 2027
-
1.3.3 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Trastuzumab from 2016 to 2027
-
1.3.4 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Adalimumab from 2016 to 2027
-
1.3.5 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Other from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Oncology from 2016 to 2027
-
1.4.2 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Autoimmune Disease from 2016 to 2027
-
1.4.3 China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Other from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Biosimilar Monoclonal Antibodies Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Biosimilar Monoclonal Antibodies by Major Types
-
3.4.1 Market Size and Growth Rate of Infliximab
-
3.4.2 Market Size and Growth Rate of Rituximab
-
3.4.3 Market Size and Growth Rate of Trastuzumab
-
3.4.4 Market Size and Growth Rate of Adalimumab
-
3.4.5 Market Size and Growth Rate of Other
4 Segmentation of Biosimilar Monoclonal Antibodies Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Biosimilar Monoclonal Antibodies by Major End-Users
-
4.4.1 Market Size and Growth Rate of Biosimilar Monoclonal Antibodies in Oncology
-
4.4.2 Market Size and Growth Rate of Biosimilar Monoclonal Antibodies in Autoimmune Disease
-
4.4.3 Market Size and Growth Rate of Biosimilar Monoclonal Antibodies in Other
5 Market Analysis by Regions
-
5.1 China Biosimilar Monoclonal Antibodies Production Analysis by Regions
-
5.2 China Biosimilar Monoclonal Antibodies Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Biosimilar Monoclonal Antibodies Landscape Analysis
-
6.1 North China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
6.2 North China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
7 Central China Biosimilar Monoclonal Antibodies Landscape Analysis
-
7.1 Central China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
7.2 Central China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
8 South China Biosimilar Monoclonal Antibodies Landscape Analysis
-
8.1 South China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
8.2 South China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
9 East China Biosimilar Monoclonal Antibodies Landscape Analysis
-
9.1 East China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
9.2 East China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
10 Northeast China Biosimilar Monoclonal Antibodies Landscape Analysis
-
10.1 Northeast China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
10.2 Northeast China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
11 Southwest China Biosimilar Monoclonal Antibodies Landscape Analysis
-
11.1 Southwest China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
11.2 Southwest China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
12 Northwest China Biosimilar Monoclonal Antibodies Landscape Analysis
-
12.1 Northwest China Biosimilar Monoclonal Antibodies Landscape Analysis by Major Types
-
12.2 Northwest China Biosimilar Monoclonal Antibodies Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Dr Reddy’s
-
13.1.1 Dr Reddy’s Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Hisun Pharma
-
13.2.1 Hisun Pharma Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 Torrent Pharmaceuticals
-
13.3.1 Torrent Pharmaceuticals Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Celgen Biopharma
-
13.4.1 Celgen Biopharma Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Pfizer (Hospira)
-
13.5.1 Pfizer (Hospira) Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 Novartis (Sandoz)
-
13.6.1 Novartis (Sandoz) Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Cadila Healthcare
-
13.7.1 Cadila Healthcare Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
-
13.8 3SBIO
-
13.8.1 3SBIO Company Profile and Recent Development
-
13.8.2 Market Performance
-
13.8.3 Product and Service Introduction
-
13.9 Celltrion
-
13.9.1 Celltrion Company Profile and Recent Development
-
13.9.2 Market Performance
-
13.9.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Infliximab from 2016 to 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Rituximab from 2016 to 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Trastuzumab from 2016 to 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Adalimumab from 2016 to 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Other from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Oncology from 2016 to 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Autoimmune Disease from 2016 to 2027
-
Figure China Biosimilar Monoclonal Antibodies Market Size and Growth Rate of Other from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Biosimilar Monoclonal Antibodies Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Biosimilar Monoclonal Antibodies
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Biosimilar Monoclonal Antibodies by Different Types from 2016 to 2027
-
Table Consumption Share of Biosimilar Monoclonal Antibodies by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Infliximab
-
Figure Market Size and Growth Rate of Rituximab
-
Figure Market Size and Growth Rate of Trastuzumab
-
Figure Market Size and Growth Rate of Adalimumab
-
Figure Market Size and Growth Rate of Other
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Biosimilar Monoclonal Antibodies by Different End-Users from 2016 to 2027
-
Table Consumption Share of Biosimilar Monoclonal Antibodies by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Oncology
-
Figure Market Size and Growth Rate of Autoimmune Disease
-
Figure Market Size and Growth Rate of Other
-
Table China Biosimilar Monoclonal Antibodies Production by Regions
-
Table China Biosimilar Monoclonal Antibodies Production Share by Regions
-
Figure China Biosimilar Monoclonal Antibodies Production Share by Regions in 2016
-
Figure China Biosimilar Monoclonal Antibodies Production Share by Regions in 2021
-
Figure China Biosimilar Monoclonal Antibodies Production Share by Regions in 2027
-
Table China Biosimilar Monoclonal Antibodies Consumption by Regions
-
Table China Biosimilar Monoclonal Antibodies Consumption Share by Regions
-
Figure China Biosimilar Monoclonal Antibodies Consumption Share by Regions in 2016
-
Figure China Biosimilar Monoclonal Antibodies Consumption Share by Regions in 2021
-
Figure China Biosimilar Monoclonal Antibodies Consumption Share by Regions in 2027
-
Table North China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table North China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table North China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table North China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure North China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table Central China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table Central China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table Central China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table Central China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure Central China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table South China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table South China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table South China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table South China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure South China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table East China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table East China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table East China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table East China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure East China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table Northeast China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table Northeast China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table Northeast China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table Northeast China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure Northeast China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table Southwest China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table Southwest China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table Southwest China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table Southwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure Southwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table Northwest China Biosimilar Monoclonal Antibodies Consumption by Types from 2016 to 2027
-
Table Northwest China Biosimilar Monoclonal Antibodies Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2016
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2021
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Share by Types in 2027
-
Table Northwest China Biosimilar Monoclonal Antibodies Consumption by End-Users from 2016 to 2027
-
Table Northwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2016
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2021
-
Figure Northwest China Biosimilar Monoclonal Antibodies Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Dr Reddy’s
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dr Reddy’s
-
Figure Sales and Growth Rate Analysis of Dr Reddy’s
-
Figure Revenue and Market Share Analysis of Dr Reddy’s
-
Table Product and Service Introduction of Dr Reddy’s
-
Table Company Profile and Development Status of Hisun Pharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hisun Pharma
-
Figure Sales and Growth Rate Analysis of Hisun Pharma
-
Figure Revenue and Market Share Analysis of Hisun Pharma
-
Table Product and Service Introduction of Hisun Pharma
-
Table Company Profile and Development Status of Torrent Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Torrent Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Torrent Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Torrent Pharmaceuticals
-
Table Product and Service Introduction of Torrent Pharmaceuticals
-
Table Company Profile and Development Status of Celgen Biopharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celgen Biopharma
-
Figure Sales and Growth Rate Analysis of Celgen Biopharma
-
Figure Revenue and Market Share Analysis of Celgen Biopharma
-
Table Product and Service Introduction of Celgen Biopharma
-
Table Company Profile and Development Status of Pfizer (Hospira)
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer (Hospira)
-
Figure Sales and Growth Rate Analysis of Pfizer (Hospira)
-
Figure Revenue and Market Share Analysis of Pfizer (Hospira)
-
Table Product and Service Introduction of Pfizer (Hospira)
-
Table Company Profile and Development Status of Novartis (Sandoz)
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis (Sandoz)
-
Figure Sales and Growth Rate Analysis of Novartis (Sandoz)
-
Figure Revenue and Market Share Analysis of Novartis (Sandoz)
-
Table Product and Service Introduction of Novartis (Sandoz)
-
Table Company Profile and Development Status of Cadila Healthcare
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cadila Healthcare
-
Figure Sales and Growth Rate Analysis of Cadila Healthcare
-
Figure Revenue and Market Share Analysis of Cadila Healthcare
-
Table Product and Service Introduction of Cadila Healthcare
-
Table Company Profile and Development Status of 3SBIO
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of 3SBIO
-
Figure Sales and Growth Rate Analysis of 3SBIO
-
Figure Revenue and Market Share Analysis of 3SBIO
-
Table Product and Service Introduction of 3SBIO
-
Table Company Profile and Development Status of Celltrion
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celltrion
-
Figure Sales and Growth Rate Analysis of Celltrion
-
Figure Revenue and Market Share Analysis of Celltrion
-
Table Product and Service Introduction of Celltrion
-
